Okechukwu Samuel Ogah, M.Sc.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nigeria | 42 | 2024 | 762 | 2.460 |
Why?
|
Hypertension | 36 | 2024 | 8594 | 1.950 |
Why?
|
Heart Failure | 24 | 2024 | 11833 | 1.170 |
Why?
|
Stroke | 26 | 2024 | 9935 | 0.940 |
Why?
|
Rheumatic Heart Disease | 6 | 2024 | 167 | 0.930 |
Why?
|
Noonan Syndrome | 1 | 2024 | 120 | 0.890 |
Why?
|
Starvation | 1 | 2022 | 140 | 0.810 |
Why?
|
Perindopril | 4 | 2022 | 13 | 0.750 |
Why?
|
Echocardiography | 16 | 2024 | 4971 | 0.670 |
Why?
|
Registries | 14 | 2021 | 8434 | 0.670 |
Why?
|
Cardiovascular Diseases | 9 | 2023 | 15728 | 0.670 |
Why?
|
Amlodipine | 5 | 2024 | 84 | 0.650 |
Why?
|
Urban Population | 4 | 2014 | 2015 | 0.630 |
Why?
|
Africa South of the Sahara | 15 | 2024 | 740 | 0.610 |
Why?
|
Ghana | 13 | 2024 | 312 | 0.570 |
Why?
|
Malnutrition | 1 | 2022 | 638 | 0.530 |
Why?
|
Africa | 12 | 2024 | 706 | 0.530 |
Why?
|
Cardiomyopathy, Hypertrophic | 2 | 2024 | 1284 | 0.520 |
Why?
|
Hypertrophy, Left Ventricular | 10 | 2019 | 853 | 0.510 |
Why?
|
Pulmonary Heart Disease | 1 | 2014 | 34 | 0.490 |
Why?
|
Antihypertensive Agents | 7 | 2024 | 2063 | 0.470 |
Why?
|
Hydrochlorothiazide | 4 | 2022 | 94 | 0.410 |
Why?
|
Vitamin K | 4 | 2024 | 321 | 0.400 |
Why?
|
Patient Readmission | 4 | 2018 | 3323 | 0.370 |
Why?
|
Blood Pressure | 13 | 2024 | 8523 | 0.360 |
Why?
|
Cardiomyopathies | 4 | 2024 | 1940 | 0.360 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2022 | 2486 | 0.350 |
Why?
|
Research Design | 3 | 2023 | 6168 | 0.340 |
Why?
|
Electrocardiography | 6 | 2024 | 6400 | 0.320 |
Why?
|
Prevalence | 14 | 2024 | 15641 | 0.310 |
Why?
|
Diabetes Mellitus | 4 | 2022 | 5880 | 0.310 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2014 | 819 | 0.310 |
Why?
|
Risk Factors | 32 | 2024 | 74167 | 0.310 |
Why?
|
Middle Aged | 63 | 2024 | 219653 | 0.300 |
Why?
|
Atrial Fibrillation | 7 | 2024 | 5198 | 0.300 |
Why?
|
Cost of Illness | 2 | 2014 | 1936 | 0.300 |
Why?
|
Cerebral Hemorrhage | 5 | 2023 | 2659 | 0.280 |
Why?
|
Life Style | 3 | 2021 | 3886 | 0.280 |
Why?
|
Heart Diseases | 3 | 2011 | 2800 | 0.280 |
Why?
|
Humans | 101 | 2024 | 759255 | 0.280 |
Why?
|
Adult | 52 | 2024 | 219390 | 0.280 |
Why?
|
Outpatients | 1 | 2014 | 1601 | 0.270 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 4 | 2022 | 253 | 0.270 |
Why?
|
Length of Stay | 3 | 2015 | 6452 | 0.270 |
Why?
|
Developing Countries | 6 | 2024 | 2876 | 0.270 |
Why?
|
Male | 67 | 2024 | 358719 | 0.260 |
Why?
|
Female | 66 | 2024 | 390240 | 0.260 |
Why?
|
Acute Disease | 9 | 2018 | 7262 | 0.260 |
Why?
|
Indapamide | 1 | 2024 | 2 | 0.250 |
Why?
|
Hypertension, Pulmonary | 4 | 2017 | 1567 | 0.240 |
Why?
|
Pericarditis, Tuberculous | 2 | 2014 | 7 | 0.230 |
Why?
|
Case-Control Studies | 20 | 2024 | 21988 | 0.230 |
Why?
|
Peripartum Period | 2 | 2021 | 138 | 0.220 |
Why?
|
Ventricular Function, Left | 7 | 2023 | 3854 | 0.210 |
Why?
|
Inpatients | 1 | 2014 | 2580 | 0.210 |
Why?
|
Coronary Artery Disease | 3 | 2023 | 6649 | 0.210 |
Why?
|
Prospective Studies | 19 | 2024 | 54204 | 0.210 |
Why?
|
Prednisolone | 2 | 2014 | 328 | 0.210 |
Why?
|
Aged | 38 | 2024 | 168617 | 0.200 |
Why?
|
Mycobacterium | 2 | 2014 | 250 | 0.200 |
Why?
|
Pneumonia, Aspiration | 1 | 2023 | 146 | 0.200 |
Why?
|
Drug Combinations | 6 | 2024 | 2023 | 0.200 |
Why?
|
Hospitalization | 9 | 2024 | 10734 | 0.190 |
Why?
|
Prognosis | 16 | 2022 | 29561 | 0.190 |
Why?
|
Myocardial Ischemia | 4 | 2021 | 2161 | 0.190 |
Why?
|
Urban Health | 2 | 2014 | 532 | 0.190 |
Why?
|
Arrhythmias, Cardiac | 3 | 2021 | 2253 | 0.180 |
Why?
|
Gross Domestic Product | 1 | 2021 | 78 | 0.180 |
Why?
|
Cause of Death | 4 | 2024 | 3721 | 0.180 |
Why?
|
Resistin | 1 | 2021 | 172 | 0.180 |
Why?
|
Prehypertension | 1 | 2021 | 63 | 0.180 |
Why?
|
Ventricular Dysfunction, Left | 5 | 2024 | 2128 | 0.180 |
Why?
|
Heart Valve Diseases | 3 | 2018 | 1048 | 0.180 |
Why?
|
Economic Recession | 1 | 2021 | 79 | 0.180 |
Why?
|
Cross-Sectional Studies | 9 | 2022 | 25860 | 0.170 |
Why?
|
Socioeconomic Factors | 4 | 2021 | 7790 | 0.170 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2021 | 137 | 0.170 |
Why?
|
Body Fat Distribution | 1 | 2021 | 243 | 0.170 |
Why?
|
Ventricular Remodeling | 3 | 2020 | 1252 | 0.170 |
Why?
|
Chloroquine | 1 | 2021 | 277 | 0.170 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2021 | 124 | 0.160 |
Why?
|
Smoking | 2 | 2016 | 9066 | 0.160 |
Why?
|
China | 2 | 2022 | 2347 | 0.160 |
Why?
|
Meta-Analysis as Topic | 1 | 2023 | 1375 | 0.150 |
Why?
|
Acute Coronary Syndrome | 2 | 2021 | 2363 | 0.150 |
Why?
|
Secondary Prevention | 1 | 2024 | 1550 | 0.150 |
Why?
|
Puerperal Disorders | 1 | 2020 | 300 | 0.150 |
Why?
|
Endocarditis | 2 | 2024 | 351 | 0.140 |
Why?
|
Disclosure | 1 | 2023 | 738 | 0.140 |
Why?
|
Drug Therapy, Combination | 6 | 2024 | 6496 | 0.140 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 428 | 0.140 |
Why?
|
Potassium | 1 | 2021 | 1318 | 0.140 |
Why?
|
Prediabetic State | 1 | 2022 | 546 | 0.140 |
Why?
|
Embolism | 1 | 2020 | 408 | 0.140 |
Why?
|
Brain Ischemia | 2 | 2023 | 3128 | 0.130 |
Why?
|
Pericardiocentesis | 2 | 2014 | 79 | 0.130 |
Why?
|
Sodium | 1 | 2021 | 1601 | 0.130 |
Why?
|
Heart Rate | 2 | 2017 | 4165 | 0.130 |
Why?
|
Quality Assurance, Health Care | 1 | 2006 | 2179 | 0.130 |
Why?
|
Heart Ventricles | 3 | 2017 | 3802 | 0.130 |
Why?
|
Adiponectin | 1 | 2021 | 1116 | 0.130 |
Why?
|
Patient Discharge | 3 | 2022 | 3460 | 0.120 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39216 | 0.120 |
Why?
|
Health Resources | 1 | 2021 | 934 | 0.120 |
Why?
|
Renal Insufficiency | 2 | 2014 | 820 | 0.120 |
Why?
|
Antimalarials | 1 | 2021 | 907 | 0.120 |
Why?
|
Anticoagulants | 4 | 2024 | 4897 | 0.110 |
Why?
|
Transportation of Patients | 1 | 2014 | 176 | 0.110 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2014 | 273 | 0.110 |
Why?
|
Myocarditis | 1 | 2021 | 767 | 0.110 |
Why?
|
Young Adult | 10 | 2021 | 58483 | 0.100 |
Why?
|
Tobacco, Smokeless | 1 | 2013 | 133 | 0.100 |
Why?
|
Stroke Volume | 6 | 2023 | 5497 | 0.100 |
Why?
|
Heart Conduction System | 1 | 2017 | 1015 | 0.100 |
Why?
|
Age Distribution | 2 | 2014 | 2892 | 0.100 |
Why?
|
Health Surveys | 2 | 2020 | 4060 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2024 | 1935 | 0.100 |
Why?
|
Rural Health | 1 | 2013 | 299 | 0.100 |
Why?
|
Health Personnel | 2 | 2023 | 3309 | 0.100 |
Why?
|
Decision Support Techniques | 1 | 2021 | 1999 | 0.090 |
Why?
|
International Normalized Ratio | 2 | 2024 | 386 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2024 | 1849 | 0.090 |
Why?
|
Multicenter Studies as Topic | 3 | 2024 | 1719 | 0.090 |
Why?
|
Pericardial Effusion | 1 | 2012 | 247 | 0.090 |
Why?
|
Transients and Migrants | 1 | 2013 | 162 | 0.090 |
Why?
|
Bacterial Vaccines | 1 | 2012 | 401 | 0.090 |
Why?
|
Risk Assessment | 7 | 2023 | 24049 | 0.090 |
Why?
|
Adolescent | 11 | 2023 | 87560 | 0.090 |
Why?
|
Age Factors | 6 | 2021 | 18394 | 0.090 |
Why?
|
Syphilis, Cardiovascular | 1 | 2009 | 2 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2532 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2021 | 4360 | 0.090 |
Why?
|
Coronary Disease | 1 | 2024 | 5993 | 0.090 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 1109 | 0.080 |
Why?
|
MEDLINE | 1 | 2009 | 119 | 0.080 |
Why?
|
Africa, Western | 2 | 2021 | 159 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1383 | 0.080 |
Why?
|
Disease | 1 | 2014 | 671 | 0.080 |
Why?
|
Malawi | 1 | 2009 | 301 | 0.080 |
Why?
|
Survival Analysis | 3 | 2018 | 10185 | 0.080 |
Why?
|
Severity of Illness Index | 2 | 2024 | 15815 | 0.080 |
Why?
|
Anemia | 1 | 2017 | 1509 | 0.070 |
Why?
|
Immunotherapy | 2 | 2014 | 4622 | 0.070 |
Why?
|
Pregnancy Complications, Cardiovascular | 2 | 2024 | 515 | 0.070 |
Why?
|
MicroRNAs | 1 | 2024 | 3797 | 0.070 |
Why?
|
Hospitals, University | 1 | 2009 | 568 | 0.070 |
Why?
|
Single-Blind Method | 3 | 2019 | 1574 | 0.070 |
Why?
|
Survival Rate | 3 | 2017 | 12800 | 0.070 |
Why?
|
Genomics | 3 | 2024 | 5775 | 0.070 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5317 | 0.070 |
Why?
|
Ultrasonography, Doppler | 1 | 2008 | 465 | 0.070 |
Why?
|
Anemia, Sickle Cell | 1 | 2014 | 1055 | 0.070 |
Why?
|
Predictive Value of Tests | 6 | 2021 | 15264 | 0.070 |
Why?
|
Epidemiologic Studies | 1 | 2009 | 669 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20031 | 0.070 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14652 | 0.060 |
Why?
|
Logistic Models | 3 | 2019 | 13309 | 0.060 |
Why?
|
Glucocorticoids | 1 | 2014 | 2142 | 0.060 |
Why?
|
Asia | 2 | 2016 | 618 | 0.060 |
Why?
|
Sex Factors | 3 | 2015 | 10518 | 0.060 |
Why?
|
Heart Atria | 2 | 2008 | 1344 | 0.060 |
Why?
|
Cohort Studies | 3 | 2022 | 41247 | 0.060 |
Why?
|
Rheumatic Fever | 1 | 2024 | 75 | 0.060 |
Why?
|
Time Factors | 5 | 2021 | 40109 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 3959 | 0.060 |
Why?
|
Incidence | 3 | 2021 | 21336 | 0.060 |
Why?
|
Hospital Mortality | 2 | 2015 | 5414 | 0.060 |
Why?
|
Retrospective Studies | 5 | 2024 | 80121 | 0.050 |
Why?
|
Residence Characteristics | 1 | 2013 | 2035 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2021 | 3087 | 0.050 |
Why?
|
Primary Prevention | 1 | 2011 | 1203 | 0.050 |
Why?
|
Arginine | 1 | 2007 | 934 | 0.050 |
Why?
|
Rural Population | 1 | 2013 | 2260 | 0.050 |
Why?
|
Thiazides | 1 | 2022 | 19 | 0.050 |
Why?
|
Ventricular Function, Right | 2 | 2017 | 610 | 0.050 |
Why?
|
Infant | 2 | 2022 | 35941 | 0.050 |
Why?
|
Systole | 2 | 2019 | 947 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2017 | 4389 | 0.050 |
Why?
|
Health Expenditures | 1 | 2014 | 2359 | 0.050 |
Why?
|
South Africa | 2 | 2022 | 1820 | 0.050 |
Why?
|
Infarction | 1 | 2023 | 248 | 0.050 |
Why?
|
Odds Ratio | 3 | 2021 | 9711 | 0.050 |
Why?
|
Health Care Costs | 1 | 2014 | 3255 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10747 | 0.050 |
Why?
|
Potassium, Dietary | 1 | 2021 | 104 | 0.050 |
Why?
|
Treatment Outcome | 7 | 2022 | 64879 | 0.050 |
Why?
|
Hand Strength | 1 | 2023 | 452 | 0.050 |
Why?
|
Diastole | 3 | 2008 | 786 | 0.050 |
Why?
|
Genome-Wide Association Study | 2 | 2024 | 12580 | 0.050 |
Why?
|
Disease Progression | 2 | 2014 | 13479 | 0.050 |
Why?
|
Qualitative Research | 2 | 2023 | 2940 | 0.040 |
Why?
|
Evidence-Based Medicine | 3 | 2018 | 3694 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 17750 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2016 | 6532 | 0.040 |
Why?
|
Observer Variation | 1 | 2006 | 2596 | 0.040 |
Why?
|
Heart Defects, Congenital | 1 | 2016 | 4663 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2022 | 691 | 0.040 |
Why?
|
Hemorrhage | 2 | 2022 | 3606 | 0.040 |
Why?
|
Morbidity | 1 | 2024 | 1764 | 0.040 |
Why?
|
Fruit | 1 | 2024 | 1162 | 0.040 |
Why?
|
Feeding Behavior | 2 | 2024 | 3183 | 0.040 |
Why?
|
Vegetables | 1 | 2024 | 1198 | 0.040 |
Why?
|
Nitric Oxide | 1 | 2007 | 2142 | 0.040 |
Why?
|
Clergy | 1 | 2018 | 79 | 0.040 |
Why?
|
Sodium, Dietary | 1 | 2021 | 425 | 0.040 |
Why?
|
Angina, Unstable | 1 | 2021 | 926 | 0.040 |
Why?
|
Cerebral Infarction | 1 | 2022 | 982 | 0.040 |
Why?
|
Awareness | 1 | 2021 | 645 | 0.030 |
Why?
|
Child | 2 | 2022 | 79623 | 0.030 |
Why?
|
Obesity | 2 | 2021 | 12896 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 3724 | 0.030 |
Why?
|
Aftercare | 1 | 2022 | 919 | 0.030 |
Why?
|
Pregnancy | 3 | 2024 | 29658 | 0.030 |
Why?
|
Middle East | 1 | 2016 | 227 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2018 | 58867 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1521 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2024 | 12522 | 0.030 |
Why?
|
Developed Countries | 1 | 2018 | 443 | 0.030 |
Why?
|
Waist-Hip Ratio | 1 | 2016 | 516 | 0.030 |
Why?
|
Apolipoprotein A-I | 1 | 2016 | 297 | 0.030 |
Why?
|
Apolipoproteins B | 1 | 2016 | 388 | 0.030 |
Why?
|
Pericarditis, Constrictive | 1 | 2014 | 46 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2009 | 12268 | 0.030 |
Why?
|
Primary Health Care | 1 | 2011 | 4639 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2024 | 2283 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2022 | 12386 | 0.030 |
Why?
|
Dyslipidemias | 1 | 2021 | 895 | 0.030 |
Why?
|
Warfarin | 1 | 2022 | 1516 | 0.030 |
Why?
|
Focus Groups | 1 | 2018 | 1367 | 0.030 |
Why?
|
Cardiac Tamponade | 1 | 2014 | 174 | 0.030 |
Why?
|
Pandemics | 2 | 2023 | 8609 | 0.030 |
Why?
|
Obesity, Abdominal | 1 | 2016 | 375 | 0.030 |
Why?
|
England | 1 | 2014 | 525 | 0.030 |
Why?
|
Echocardiography, Doppler | 2 | 2008 | 900 | 0.030 |
Why?
|
Australia | 1 | 2016 | 1287 | 0.030 |
Why?
|
Myocardial Contraction | 1 | 2017 | 1516 | 0.030 |
Why?
|
Health Education | 1 | 2018 | 1049 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2019 | 1826 | 0.020 |
Why?
|
Family | 1 | 2023 | 3189 | 0.020 |
Why?
|
Penicillins | 1 | 2014 | 400 | 0.020 |
Why?
|
Organ Size | 2 | 2008 | 2248 | 0.020 |
Why?
|
Genetics, Medical | 1 | 2014 | 336 | 0.020 |
Why?
|
Health | 1 | 2014 | 395 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2014 | 786 | 0.020 |
Why?
|
Pilot Projects | 2 | 2014 | 8540 | 0.020 |
Why?
|
Ultrasonography | 3 | 2009 | 5955 | 0.020 |
Why?
|
Action Potentials | 1 | 2017 | 1810 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7237 | 0.020 |
Why?
|
Heart | 1 | 2023 | 4390 | 0.020 |
Why?
|
International Cooperation | 1 | 2016 | 1436 | 0.020 |
Why?
|
Genetic Testing | 1 | 2023 | 3531 | 0.020 |
Why?
|
Sex Distribution | 1 | 2014 | 2294 | 0.020 |
Why?
|
Antibiotic Prophylaxis | 1 | 2014 | 640 | 0.020 |
Why?
|
Europe | 1 | 2016 | 3429 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3930 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2016 | 1342 | 0.020 |
Why?
|
Body Surface Area | 1 | 2009 | 197 | 0.020 |
Why?
|
Pulmonary Artery | 1 | 2017 | 1910 | 0.020 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2014 | 615 | 0.020 |
Why?
|
Creatinine | 1 | 2014 | 1907 | 0.020 |
Why?
|
Mass Screening | 1 | 2024 | 5419 | 0.020 |
Why?
|
Seizures | 1 | 2021 | 2908 | 0.020 |
Why?
|
Treatment Failure | 1 | 2014 | 2642 | 0.020 |
Why?
|
Blood Glucose | 1 | 2022 | 6368 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7460 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10547 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2018 | 3556 | 0.020 |
Why?
|
Administration, Oral | 1 | 2014 | 4046 | 0.020 |
Why?
|
Caregivers | 1 | 2018 | 2214 | 0.020 |
Why?
|
Motor Activity | 1 | 2016 | 2687 | 0.020 |
Why?
|
Poverty | 1 | 2018 | 2682 | 0.020 |
Why?
|
Biological Availability | 1 | 2007 | 395 | 0.020 |
Why?
|
Body Mass Index | 3 | 2009 | 12874 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2014 | 2168 | 0.020 |
Why?
|
Diet | 1 | 2024 | 8002 | 0.020 |
Why?
|
Brachial Artery | 1 | 2007 | 368 | 0.020 |
Why?
|
Self Report | 1 | 2016 | 3699 | 0.020 |
Why?
|
Health Behavior | 1 | 2016 | 2619 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2024 | 15750 | 0.010 |
Why?
|
Antitubercular Agents | 1 | 2012 | 1374 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2012 | 1870 | 0.010 |
Why?
|
Brain | 2 | 2023 | 26863 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2016 | 4006 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 2007 | 1490 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 10333 | 0.010 |
Why?
|
Body Height | 1 | 2009 | 1570 | 0.010 |
Why?
|
Vasodilation | 1 | 2007 | 964 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2014 | 8549 | 0.010 |
Why?
|
Chronic Disease | 1 | 2017 | 9282 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5377 | 0.010 |
Why?
|
Phenotype | 1 | 2017 | 16532 | 0.010 |
Why?
|
Body Weight | 1 | 2009 | 4608 | 0.010 |
Why?
|
Reference Values | 1 | 2005 | 4918 | 0.010 |
Why?
|
Regression Analysis | 1 | 2007 | 6359 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 7380 | 0.010 |
Why?
|
Hemodynamics | 1 | 2006 | 4164 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2007 | 4435 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2017 | 20461 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 12152 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 36160 | 0.010 |
Why?
|
HIV Infections | 1 | 2014 | 17128 | 0.000 |
Why?
|
United States | 1 | 2014 | 72237 | 0.000 |
Why?
|